Lixte Biotechnology Holdings (LIXT) EBIAT (2016)
Lixte Biotechnology Holdings' EBIAT history spans 7 years, with the latest figure at -$516257.0 for Q4 2016.
- For Q4 2016, EBIAT changed N/A year-over-year to -$516257.0; the TTM value through Dec 2016 reached -$2.1 million, changed N/A, while the annual FY2025 figure was -$6.1 million, 69.51% down from the prior year.
- EBIAT reached -$516257.0 in Q4 2016 per LIXT's latest filing, up from -$646936.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$313051.0 in Q3 2013 to a low of -$13.0 million in Q4 2013.
- Average EBIAT over 5 years is -$2.0 million, with a median of -$619397.0 recorded in 2012.
- Peak YoY movement for EBIAT: tumbled 182.92% in 2012, then skyrocketed 84.17% in 2013.
- A 5-year view of EBIAT shows it stood at -$11.6 million in 2012, then decreased by 11.88% to -$13.0 million in 2013, then skyrocketed by 96.13% to -$501393.0 in 2014, then tumbled by 55.5% to -$779687.0 in 2015, then soared by 33.79% to -$516257.0 in 2016.
- Per Business Quant, the three most recent readings for LIXT's EBIAT are -$516257.0 (Q4 2016), -$646936.0 (Q3 2016), and -$554996.0 (Q2 2016).